Frontlight ResearchEarly access
Ovarian cancer trials in Netherlands
26 of 31 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Amsterdam, Groningen, Leiden, Maastricht, Nijmegen
- Age
- 18 years and over
- People
- 890 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 3Not yet taking people in NetherlandsA Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Where
- Amsterdam, Groningen, Nijmegen
- Age
- 18 years and over
- People
- 420 worldwide
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500 - Phase 1Not yet taking people in NetherlandsA Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Where
- Amsterdam, Maastricht, Nijmegen, Utrecht
- Age
- 18 years and over
- People
- 340 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00 - Phase 3Taking peopleA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Where
- Groningen, Rotterdam
- Age
- 18 years and over
- People
- 1,630 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00 - Phase 3Not yet taking people in NetherlandsStudy to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
- Where
- Amsterdam, Groningen
- Age
- 18 years and over
- People
- 688 worldwide
- Run by
- Genmab
See details and how to joinNCT07564141 · EU 2025-524202-15-00 - Phase 3Taking peopleA Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- Where
- Amsterdam, Nijmegen
- Age
- 18 years and over
- People
- 270 worldwide
- Run by
- Verastem, Inc.
See details and how to joinNCT06072781 · EU 2023-508204-38-00 - Phase 1/2Taking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Amsterdam, Groningen, Nijmegen, Rotterdam, Utrecht
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - Phase 1Not yet taking people in NetherlandsAn open-label phase 1 dose-escalation study to evaluate safety, tolerability, pharmacokinetics, and exploratory assessments of PACAB-002 in patients with ovarian cancer with peritoneal spread
- Where
- Rotterdam
- Age
- 18 years and over
- People
- 21
- Run by
- Nadeno Nanoscience AS
See details and how to join2026-527184-15-00 - Phase 1/2Taking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Amsterdam
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - Phase 1/2Taking peopleExploiting the synergistic effect of PARP inhibition with cisplatin and hyperthermia during interval cytoreductive surgery and HIPEC in ovarian cancer: The PROOV study - A Phase I/II clinical trial
- Where
- Amsterdam, Utrecht
- Age
- 18 years and over
- People
- 55
- Run by
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
See details and how to join2024-519170-39-00 - Phase 1/2Taking peopleStudy of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Where
- Groningen, Nijmegen, Rotterdam
- Age
- 18 years and over
- People
- 890 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT03564340 · EU 2024-510783-23-00 - Phase 1/2Taking peopleStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Where
- Amsterdam
- Age
- 18 years and over
- People
- 534 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06128551 - Phase 2Taking people[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- Where
- Groningen, Nijmegen
- Age
- 18 years to 79 years
- People
- 71 worldwide
- Run by
- Blue Earth Diagnostics
See details and how to joinNCT07702292 · EU 2025-521983-36-00 - Phase 3Taking peopleMinimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- Where
- Amsterdam
- Age
- 18 years and over
- People
- 580 worldwide
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT04575935 - Phase 3Not yet taking people in NetherlandsUtility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
- Where
- Amsterdam, Leiden, Nijmegen, Rotterdam
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- ARCAGY/ GINECO GROUP
See details and how to joinNCT06476184 - Phase 2Taking peopleA Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Where
- Rotterdam
- Age
- 8 years and over
- People
- 254 worldwide
- Run by
- Fore Biotherapeutics
See details and how to joinNCT05503797 · EU 2024-513578-23-00 - Phase 1/2Taking peopleFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Where
- Amsterdam, Rotterdam
- Age
- 18 years and over
- People
- 880 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00 - Phase 2/3Not yet taking people in NetherlandsStudy to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
- Where
- Nieuwegein
- Age
- 18 years and over
- People
- 175 worldwide
- Run by
- GE Healthcare
See details and how to joinNCT07219238 · EU 2024-519384-18-00 - Phase 2Taking peopleAbemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
- Where
- Groningen, Rotterdam, Utrecht
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- Universitaire Ziekenhuizen KU Leuven
See details and how to joinNCT05872204 · EU 2023-503533-21-00 - No phaseTaking peopleTUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
- Where
- Amsterdam, Breda, Eindhoven, Enschede, Groningen, Leeuwarden, Leiden, Maastricht, Nijmegen, Rotterdam, Tilburg, Utrecht, Veldhoven, Zwolle
- Age
- 25 years to 50 years
- People
- 3,000 worldwide
- Run by
- University Medical Center Nijmegen
See details and how to joinNCT04294927 - Phase 1/2Taking peopleThe PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer
- Where
- Amsterdam
- Age
- 18 years to 100 years
- People
- 55
- Run by
- The Netherlands Cancer Institute
See details and how to joinNCT07460180 - No phaseTaking peopleOveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study
- Where
- Eindhoven
- Age
- 18 years and over
- People
- 90
- Run by
- Gynaecologisch Oncologisch Centrum Zuid
See details and how to joinNCT06611072 - Phase 1/2Taking peopleOVACURE-2
- Where
- Leiden
- Age
- 18 years and over
- People
- 30
- Run by
- Leids Universitair Medisch Centrum (LUMC)
See details and how to join2025-522659-24-00 - Phase 1/2CompletedNEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer
- Where
- Nijmegen
- Age
- 18 years and over
- People
- 10
- Run by
- Radboud University Medical Center
See details and how to joinNCT05773859 · EU 2024-512353-24-01 - Phase 1/2Taking peoplePhase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
- Where
- Maastricht, Rotterdam
- Age
- 18 years and over
- People
- 126 worldwide
- Run by
- Maastricht University Medical Center
See details and how to joinNCT04954599